Drug Trial Radar · NCT06290349
Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
174
Actual
Start
Apr 1, 2024
Primary completion
Sep 5, 2025
Study completion Mar 31, 2026
Sponsor
- Lead sponsor
- Dong-A ST Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the efficacy and safety of adding the SGLT-2 inhibitor DA5221-T to the combination therapy of DA5221-B1 and the DPP-4 inhibitor DA5221-B2 in patients with type 2 diabetes who have inadequate blood glucose control. The study focuses on assessing the effectiveness and safety of the triple combination therapy.
Conditions
- Type 2 Diabetes
Interventions
DA5221-T1Drug
DA5221-T1 + DA5221-R2, orally, once daily, up to 24 weeks
DA5221-T2Drug
DA5221-R1 + DA5221-T2, orally, once daily, up to 24 weeks
PlaceboDrug
DA5221-R1 + DA5221-R2, orally, once daily, up to 24 weeks
DA5221-B1Drug
DA5221-B1, orally, daily for background therapy
DA5221-B2Drug
DA5221-B2, orally, daily for background therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from the baseline in HbA1c (%) after 24 weeksTime frame: Baseline, 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Severance Hospital, Yonsei University college of Medicine
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.